Jul. 17 at 3:41 PM
$ANGO Angiodynamics reported fiscal Q4 net sales of
$86.6M, up 8% year over year and ahead of estimates.
The growth is coming from its Med Tech segment, where sales rose 16.7% and NanoKnife jumped 64.5%. That mix shift lifted gross margin to 54%. For fiscal 2027, management guided to Med Tech growth of 12-15%.
One sell-side firm reiterated its Buy rating and raised its price target to
$19 from
$16.
https://prismmarketview.com/companies/angiodynamics-inc/#about
